- Home
- FLUX vs BOLD Comparison
FLUX vs BOLD Comparison
Compare FLUX & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FLUX | BOLD |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Miscellaneous | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.1M | 25.7M |
| IPO Year | 2019 | 2024 |
Fundamental Metrics
Financial Performance| Metric | FLUX | BOLD |
|---|---|---|
| Price | $1.21 | $1.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $8.00 | $4.00 |
| AVG Volume (30 Days) | ★ 175.3K | 50.5K |
| Earning Date | 05-07-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 20.00 | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,317,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 126.25 | N/A |
| 52 Week Low | $1.01 | $0.96 |
| 52 Week High | $7.55 | $1.78 |
Technical Indicators
Market Signals| Indicator | FLUX | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 39.51 | 50.73 |
| Support Level | $1.04 | $1.15 |
| Resistance Level | $1.52 | $1.19 |
| Average True Range (ATR) | 0.11 | 0.04 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 12.89 | 45.83 |
Price Performance
Historical ComparisonAbout FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.